VolitionRXVNRX
VNRX
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
27% more funds holding
Funds holding: 22 [Q3] → 28 (+6) [Q4]
6% more capital invested
Capital invested by funds: $10.5M [Q3] → $11.2M (+$680K) [Q4]
0.44% more ownership
Funds ownership: 19.03% [Q3] → 19.48% (+0.44%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$5
862%
upside
Avg. target
$5
862%
upside
High target
$5
862%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 30% 1-year accuracy 98 / 328 met price target | 862%upside $5 | Buy Maintained | 1 Apr 2025 |
Financial journalist opinion
Based on 12 articles about VNRX published over the past 30 days
Neutral
Seeking Alpha
14 hours ago
VolitionRx Limited (VNRX) Q4 2024 Earnings Call Transcript
VolitionRx Limited (NYSE:VNRX ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Louise Batchelor - Chief Marketing & Communications Officer Cameron Reynolds - President & Chief Executive Officer Terig Hughes - Chief Financial Officer Andrew Retter - Chief Medical Officer Conference Call Participants Bruce Jackson - The Benchmark Company Ilya Zubkov - Freedom Broker Steven Ralston - Zacks Investment Research Operator Good afternoon ladies and gentlemen and thank you for standing by. Welcome to VolitionRx Limited Fourth Quarter and Full Fiscal Year 2024 Earnings Conference Call.
Neutral
PRNewsWire
23 hours ago
VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Monday, March 31 at 4:30 p.m. U.S. Eastern Time HENDERSON, Nevada , March 31, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the fourth quarter and full fiscal year ended December 31, 2024.
Neutral
PRNewsWire
4 days ago
Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025
Studies demonstrate how Volition's Nu.Q®H3K27Me3 biomarker, when combined with ctDNA, may improve the prognostic value for overall survival and could help inform treatment decisions in NSCLC; and how Volition's Nu.Q® H3.1, low-cost immunoassay may be utilized for the early identification of subjects at high risk of cancer HENDERSON, Nev. , March 28, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two poster presentations at the European Society for Medical Oncology (ESMO)'s European Lung Cancer Congress 2025 (ELCC 2025).
Neutral
PRNewsWire
5 days ago
Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025
HENDERSON, Nev. , March 27, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces it will host a virtual investor event on Wednesday, April 9, 2025, at 10:00 AM ET, featuring Volition's Gael Forterre, Chief Commercial Officer, Dr. Andrew Retter, Chief Medical Officer and Dr. Jake Micallef, Chief Scientific Officer.
Neutral
PRNewsWire
6 days ago
VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering
Up to $2.3 million up front with up to an additional $1.1 million of potential aggregate gross proceeds upon the exercise in full of common stock purchase warrants HENDERSON, Nev. , March 26, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announces today that it has entered into definitive agreements for the purchase and sale of (i) 2,363,636 shares of its common stock to certain directors, executive officers, and certain existing stockholders of the Company (collectively, the "Insiders") at an offering price of $0.55 per share, and (ii) 1,739,087 shares of its common stock, together with common stock purchase warrants to purchase up to 1,739,087 shares of common stock (individually, a "Warrant" and collectively, the "Warrants"), to certain other existing stockholders of the Company and new investors at a combined offering price of $0.55 per share and accompanying Warrant.
Neutral
PRNewsWire
1 week ago
VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update
Conference call to take place on Monday, March 31 at 4:30 p.m. U.S Eastern Time HENDERSON, Nev.
Neutral
PRNewsWire
1 week ago
Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry
Volition study shows rapid, low-cost, automated Nu.Q® Cancer test accurately detects human cancers at high specificity HENDERSON, Nev. , March 21, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ('Volition'), a multi-national epigenetics company, today announces the results of a study which shows that an automated Nu.Q® Cancer immunoassay test in development detected a range of 21 different cancers.
Neutral
PRNewsWire
1 week ago
Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer
"Lung Cancer: Hope of a Brighter Tomorrow" illustrates how Nu.Q® Cancer Test aims to transform the diagnosis, treatment and monitoring in the $4 billion lung cancer market1 HENDERSON, Nev. , March 20, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of Volition's new lung cancer primer, "Lung Cancer: Hope of a Brighter Tomorrow.
Neutral
PRNewsWire
2 weeks ago
Volition Proudly Sponsors the 44th ISICEM Congress
Volition to host multiple presentations at the International Symposium on Intensive Care & Emergency Medicine in Brussels, Belgium, from March 18 - 21 HENDERSON, Nev. , March 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced its participation at the 44th Annual ISICEM ("International Symposium on Intensive Care & Emergency Medicine") Congress in Brussels Belgium being held from March 18-21.
Neutral
PRNewsWire
2 weeks ago
Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems
HENDERSON, Nev. , March 13, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the expansion of its Nu.Q® Vet Cancer Test supply agreement (the "Agreement") with Fujifilm Vet Systems Co. Ltd ("Fujifilm Vet Systems") in Japan, to include Volition's chemiluminescent immunoassay (ChLIA) version of the Test via the Immunodiagnostic Systems (IDS) i10® automated analyzer platform, for a new five year initial term.
Charts implemented using Lightweight Charts™